Yuan Lin
Research Subjects
Yuan Lin has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Liao
Department of Preclinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd , Lianyungang, Jiangsu 222047
45 shared publications - Xing Sun
Jiangsu Hengrui Pharmaceuticals Co. Ltd, Lianyungang, China
44 shared publications - Changyong Yang
Jiangsu Hengrui Pharmaceuticals Co. Ltd, Lianyungang, China
28 shared publications - Jiayi Li
State Key Laboratory of Microbial Metabolism Joint International Research Laboratory of Metabolic & Developmental Sciences School of Life Sciences & Biotechnology Shanghai Jiao Tong University Shanghai People's Republic of China
17 shared publications - Jieqiong Zhang
Jiangsu Hengrui Pharmaceuticals Co. Ltd, Lianyungang, China
17 shared publications - Lei Zhou
Shanghai Shengdi Pharmaceutical Co., Ltd., Shanghai, China
17 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Supplementary Figure S4: Binding Kinetics of the TIGIT-8-PVRIG-30-IgG4 BsAb (SHR-2002) to Human, Cynomolgus, and Mouse TIGIT and PVRIG Proteins
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Supplementary Figure S4: Binding Kinetics of the TIGIT-8-PVRIG-30-IgG4 BsAb (SHR-2002) to Human, Cynomolgus, and Mouse TIGIT and PVRIG Proteins
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Supplementary Figure S5: Tissue Distribution of SHR-2002 in Monkeys After Injection
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Supplementary Figure S5: Tissue Distribution of SHR-2002 in Monkeys After Injection
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Supplementary Figure S3: Antibody Validation of TIGIT-8-PVRIG-30-IgG4 BsAb (SHR-2002)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Supplementary Figure S3: Antibody Validation of TIGIT-8-PVRIG-30-IgG4 BsAb (SHR-2002)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Supplementary Figure S1. Expression of PD-1, TIGIT and PVRIG by Single-Cell Sequencing Analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Supplementary Figure S1. Expression of PD-1, TIGIT and PVRIG by Single-Cell Sequencing Analysis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Supplementary Table S2: Anti-Drug Antibody Concentration After SHR-2002 Injection in Monkeys
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Supplementary Table S2: Anti-Drug Antibody Concentration After SHR-2002 Injection in Monkeys
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Supplementary Figure S2: Specific Binding of the Tiragolumab Analogue to TIGIT and CPA.7.021 to PVRIG
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Supplementary Figure S2: Specific Binding of the Tiragolumab Analogue to TIGIT and CPA.7.021 to PVRIG
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Supplementary Table S1: Fluorescent Antibodies Used for Flow Cytometry in This Study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Supplementary Table S1: Fluorescent Antibodies Used for Flow Cytometry in This Study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) and poliovirus receptor–related immunoglobulin domain (PVRIG) are immune checkpoints co-expressed on activated T and NK cells, contributing to tumor immune evasion. Simultaneous blockade of these pathways may enhance therapeutic efficacy, positioning them as promising dual targets for cancer immunotherapy. This study aimed to develop a bispecific antibody (BsAb) to co-target TIGIT and PVRIG. Expression of TIGIT and PVRIG was assessed on tumor-infiltrating lymphocytes from patients with various cancers, including non–small cell lung cancer (n = 63) and colorectal cancer (n = 26). The BsAb was engineered by fusing anti-PVRIG nanobodies to the N terminus of anti-TIGIT antibodies. Functional characterization of the BsAb was performed in vitro and in vivo, including assessments of T- and NK-cell activation and cytotoxicity. Pharmacokinetics and safety profiles were evaluated in cynomolgus monkeys. Statistical analyses were conducted using the Student t test. The results showed that the BsAb effectively blocked TIGIT and PVRIG from binding their respective ligands, CD155 and CD112, leading to significant increases in T-cell activation (2.8-fold; P < 0.05) and NK-cell cytotoxicity (1.8-fold; P < 0.05). In vivo, the BsAb demonstrated potent antitumor activity, both as a monotherapy and in combination with anti–PD-1 or anti–PD-L1, in humanized peripheral blood mononuclear cell–reconstituted and transgenic mouse models. Pharmacokinetic studies in cynomolgus monkeys revealed a favorable profile, with no dose-limiting toxicities observed after four repeated doses of 200 mg/kg. These findings provide compelling preclinical evidence for the therapeutic potential of targeting the TIGIT–PVRIG axis with a BsAb. This approach shows promise for enhancing antitumor immunity and warrants further investigation in clinical trials.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) and poliovirus receptor–related immunoglobulin domain (PVRIG) are immune checkpoints co-expressed on activated T and NK cells, contributing to tumor immune evasion. Simultaneous blockade of these pathways may enhance therapeutic efficacy, positioning them as promising dual targets for cancer immunotherapy. This study aimed to develop a bispecific antibody (BsAb) to co-target TIGIT and PVRIG. Expression of TIGIT and PVRIG was assessed on tumor-infiltrating lymphocytes from patients with various cancers, including non–small cell lung cancer (n = 63) and colorectal cancer (n = 26). The BsAb was engineered by fusing anti-PVRIG nanobodies to the N terminus of anti-TIGIT antibodies. Functional characterization of the BsAb was performed in vitro and in vivo, including assessments of T- and NK-cell activation and cytotoxicity. Pharmacokinetics and safety profiles were evaluated in cynomolgus monkeys. Statistical analyses were conducted using the Student t test. The results showed that the BsAb effectively blocked TIGIT and PVRIG from binding their respective ligands, CD155 and CD112, leading to significant increases in T-cell activation (2.8-fold; P < 0.05) and NK-cell cytotoxicity (1.8-fold; P < 0.05). In vivo, the BsAb demonstrated potent antitumor activity, both as a monotherapy and in combination with anti–PD-1 or anti–PD-L1, in humanized peripheral blood mononuclear cell–reconstituted and transgenic mouse models. Pharmacokinetic studies in cynomolgus monkeys revealed a favorable profile, with no dose-limiting toxicities observed after four repeated doses of 200 mg/kg. These findings provide compelling preclinical evidence for the therapeutic potential of targeting the TIGIT–PVRIG axis with a BsAb. This approach shows promise for enhancing antitumor immunity and warrants further investigation in clinical trials.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
CD40 expression in normal human and rhesus tissues by immunohistochemistry.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
CD40 expression in normal human and rhesus tissues by immunohistochemistry.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The binding ability of 9E5 to TNF family members.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The binding ability of 9E5 to TNF family members.